CVS Health Introduces Biosimilar Policy Changes for Bone Disease Treatments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2026
0mins
Source: seekingalpha
- Biosimilar Introduction: CVS Health announced the inclusion of biosimilars Prolia and Forteo in its commercial formularies, replacing brand-name drugs from Amgen and Eli Lilly, expected to provide over 50% cost savings for patients.
- Significant Cost Savings: The low-cost alternatives from CVS's biosimilar unit Cordavis and companies like Celltrion will help generate $1.5 billion in gross savings for customers and patients, significantly reducing the financial burden of osteoporosis treatments.
- Implementation Timeline: These formulary changes will take effect on April 1, with CVS Caremark overseeing the execution, ensuring customers and members have access to more competitive treatment options.
- Market Strategy Shift: By prioritizing biosimilar adoption, CVS not only enhances patient affordability but also strengthens its competitive position in the healthcare market, aligning with the industry's urgent need to lower drug costs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to fall
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 104.660
Low
91.00
Averages
96.71
High
105.00
Current: 104.660
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. The Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and, through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SpaceX IPO Performance and Market Dynamics
- SpaceX IPO Performance: SpaceX's IPO was priced at $135 per share, closing at $153 on Thursday, down from a peak of $225.64, indicating increased market volatility that investors should monitor closely for future performance.
- Analyst Rating Distribution: Currently, nine analysts cover SpaceX, with five rating it a buy according to FactSet, reflecting confidence in its growth potential; however, Morningstar's price target of $62 suggests a divergence in market expectations.
- CVS Stock Performance: CVS has surged 45% over the past three months, hitting a new high on Thursday, with 25 analysts giving it an overweight or buy rating, indicating strong market performance and investor confidence.
- Market Dynamics Observation: The tech and communication services sectors are underperforming, while healthcare and utilities have risen by 4.6% and 3% respectively, reflecting investors' preference for more stable investments in an uncertain market environment.
See More
Florida Launches Antitrust Investigation into CVS Health
- Investigation Launched: The Florida Attorney General's Office has initiated an antitrust investigation into CVS Health Corporation to determine if the company is leveraging its dual ownership of retail pharmacies and Caremark to unfairly eliminate independent competitors and manipulate drug choices for consumers in Florida.
- Market Dominance Concerns: With CVS Health operating over 9,000 pharmacies nationwide, including approximately 800 in Florida, and Caremark managing about 80% of U.S. prescriptions, there are significant concerns regarding self-preferencing and vertical integration that could limit drug options for patients.
- Impact on Small Pharmacies: The probe will examine whether CVS/Caremark employs tactics such as offering higher reimbursements to its own pharmacies, imposing burdensome audits, and enforcing restrictive contracts that threaten the viability of small pharmacies, potentially leading to closures and the creation of “pharmacy deserts.”
- Strict Compliance Requirements: The Civil Investigative Demand mandates CVS to provide thousands of documents and sworn testimonies regarding reimbursement rates, pharmacy contracts, patient steering, audits, rebates, and differential treatment between its own and independent stores, with compliance required by July 28, 2026, highlighting the seriousness and potential implications of the investigation.
See More
Grand Opening of Mews at St. Mary in New Jersey Celebrated
- Community Achievement: The Mews at St. Mary community in Williamstown, New Jersey, officially opened, providing 75 affordable homes designed for seniors, aimed at fostering community friendship and support to enhance the quality of life for the elderly.
- Health Services Provided: This community features not only senior-friendly designs but also an on-site wellness nurse and resident-driven programming, ensuring that residents receive necessary health support and social interaction in a safe environment.
- Employee Engagement: CVS Health and Aetna employees assembled 75 welcome baskets the day before the opening, filled with essential items, reflecting the company's commitment to community care and enhancing team cohesion among staff.
- Corporate Social Responsibility: CVS Health-Aetna showcases its “Housing is Healthcare” philosophy by supporting the development of Mews at St. Mary, emphasizing the company's long-term commitment to improving community quality of life.
See More
CVS Health Expands Support for GLP-1 Weight Loss Medications
- Positive Market Reaction: CVS Health's announcement to expand support for GLP-1 weight loss medications led to a 3% stock price increase, contrasting sharply with the S&P 500's slight 0.2% decline, indicating strong investor confidence in the company's strategic direction.
- New Service Launch: CVS introduced a new specialty MinuteClinic virtual visit service focused on GLP-1 prescriptions and administration, priced at $49 per visit, aimed at improving patient access to medications and adherence to treatment regimens.
- Medicare Participation Program: Starting July 1, CVS will participate in the Medicare GLP-1 Bridge Program, a federal discount initiative expected to attract more qualifying patients, further driving business growth in the weight loss medication market.
- Significant Market Potential: With soaring demand for obesity medications among American consumers, CVS's expansion not only enhances its market share but also positions it as one of the most attractive pharmacy stocks in the U.S.
See More
CVS Expands Support for Weight-Loss Medications
- Market Expansion Plan: CVS Health announced it will expand support for GLP-1 weight-loss medications across its U.S. pharmacies and MinuteClinics, which is expected to attract more consumers seeking weight-loss drugs, thereby increasing market share.
- New Service Launch: CVS introduced a new specialty MinuteClinic virtual visit offering focused on GLP-1 prescriptions and management, priced at $49 per visit, aimed at improving patient adherence and treatment outcomes.
- Medicare Discount Program: Starting July 1, CVS will participate in the Medicare GLP-1 Bridge Program, a federal discount initiative that will provide more attractive drug pricing for qualifying patients, further enhancing CVS's competitiveness in the weight-loss medication market.
- Positive Stock Market Reaction: CVS's stock rose by 3% following this expansion plan, contrasting with a slight 0.2% decline in the S&P 500 index, indicating investor confidence in the company's new strategy and optimistic market outlook.
See More
CVS Launches $49 Virtual Clinic Visits for GLP-1 Prescriptions
- Virtual Clinic Service: CVS Health has launched a $49 MinuteClinic virtual visit service, allowing customers to consult with clinicians who may prescribe GLP-1 weight loss drugs, available in 47 states and Washington, D.C., aimed at self-pay customers to enhance the company's competitive edge in health management.
- No Membership Fee: The service does not require a membership fee, further lowering the barrier for customer access, which is expected to attract more consumers seeking convenient healthcare services, thereby driving CVS's customer base and revenue growth.
- Medicare Participation Program: CVS announced its participation in the CMS Medicare GLP-1 Bridge program from July 1, 2026, to December 31, 2027, allowing eligible Medicare beneficiaries to purchase certain GLP-1 medications for $50 per month, enhancing the company's influence in the senior healthcare market.
- Positive Market Response: This new initiative is viewed as a compelling turnaround opportunity for CVS, with analysts expressing optimism about its improving financial metrics and potential market recovery, which is expected to elevate CVS's overall valuation in the healthcare sector.
See More
SpaceX IPO Performance and Market Dynamics
- SpaceX IPO Performance: SpaceX's IPO was priced at $135 per share, closing at $153 on Thursday, down from a peak of $225.64, indicating increased market volatility that investors should monitor closely for future performance.
- Analyst Rating Distribution: Currently, nine analysts cover SpaceX, with five rating it a buy according to FactSet, reflecting confidence in its growth potential; however, Morningstar's price target of $62 suggests a divergence in market expectations.
- CVS Stock Performance: CVS has surged 45% over the past three months, hitting a new high on Thursday, with 25 analysts giving it an overweight or buy rating, indicating strong market performance and investor confidence.
- Market Dynamics Observation: The tech and communication services sectors are underperforming, while healthcare and utilities have risen by 4.6% and 3% respectively, reflecting investors' preference for more stable investments in an uncertain market environment.
See More
Florida Launches Antitrust Investigation into CVS Health
- Investigation Launched: The Florida Attorney General's Office has initiated an antitrust investigation into CVS Health Corporation to determine if the company is leveraging its dual ownership of retail pharmacies and Caremark to unfairly eliminate independent competitors and manipulate drug choices for consumers in Florida.
- Market Dominance Concerns: With CVS Health operating over 9,000 pharmacies nationwide, including approximately 800 in Florida, and Caremark managing about 80% of U.S. prescriptions, there are significant concerns regarding self-preferencing and vertical integration that could limit drug options for patients.
- Impact on Small Pharmacies: The probe will examine whether CVS/Caremark employs tactics such as offering higher reimbursements to its own pharmacies, imposing burdensome audits, and enforcing restrictive contracts that threaten the viability of small pharmacies, potentially leading to closures and the creation of “pharmacy deserts.”
- Strict Compliance Requirements: The Civil Investigative Demand mandates CVS to provide thousands of documents and sworn testimonies regarding reimbursement rates, pharmacy contracts, patient steering, audits, rebates, and differential treatment between its own and independent stores, with compliance required by July 28, 2026, highlighting the seriousness and potential implications of the investigation.
See More
Grand Opening of Mews at St. Mary in New Jersey Celebrated
- Community Achievement: The Mews at St. Mary community in Williamstown, New Jersey, officially opened, providing 75 affordable homes designed for seniors, aimed at fostering community friendship and support to enhance the quality of life for the elderly.
- Health Services Provided: This community features not only senior-friendly designs but also an on-site wellness nurse and resident-driven programming, ensuring that residents receive necessary health support and social interaction in a safe environment.
- Employee Engagement: CVS Health and Aetna employees assembled 75 welcome baskets the day before the opening, filled with essential items, reflecting the company's commitment to community care and enhancing team cohesion among staff.
- Corporate Social Responsibility: CVS Health-Aetna showcases its “Housing is Healthcare” philosophy by supporting the development of Mews at St. Mary, emphasizing the company's long-term commitment to improving community quality of life.
See More
CVS Health Expands Support for GLP-1 Weight Loss Medications
- Positive Market Reaction: CVS Health's announcement to expand support for GLP-1 weight loss medications led to a 3% stock price increase, contrasting sharply with the S&P 500's slight 0.2% decline, indicating strong investor confidence in the company's strategic direction.
- New Service Launch: CVS introduced a new specialty MinuteClinic virtual visit service focused on GLP-1 prescriptions and administration, priced at $49 per visit, aimed at improving patient access to medications and adherence to treatment regimens.
- Medicare Participation Program: Starting July 1, CVS will participate in the Medicare GLP-1 Bridge Program, a federal discount initiative expected to attract more qualifying patients, further driving business growth in the weight loss medication market.
- Significant Market Potential: With soaring demand for obesity medications among American consumers, CVS's expansion not only enhances its market share but also positions it as one of the most attractive pharmacy stocks in the U.S.
See More
CVS Expands Support for Weight-Loss Medications
- Market Expansion Plan: CVS Health announced it will expand support for GLP-1 weight-loss medications across its U.S. pharmacies and MinuteClinics, which is expected to attract more consumers seeking weight-loss drugs, thereby increasing market share.
- New Service Launch: CVS introduced a new specialty MinuteClinic virtual visit offering focused on GLP-1 prescriptions and management, priced at $49 per visit, aimed at improving patient adherence and treatment outcomes.
- Medicare Discount Program: Starting July 1, CVS will participate in the Medicare GLP-1 Bridge Program, a federal discount initiative that will provide more attractive drug pricing for qualifying patients, further enhancing CVS's competitiveness in the weight-loss medication market.
- Positive Stock Market Reaction: CVS's stock rose by 3% following this expansion plan, contrasting with a slight 0.2% decline in the S&P 500 index, indicating investor confidence in the company's new strategy and optimistic market outlook.
See More
CVS Launches $49 Virtual Clinic Visits for GLP-1 Prescriptions
- Virtual Clinic Service: CVS Health has launched a $49 MinuteClinic virtual visit service, allowing customers to consult with clinicians who may prescribe GLP-1 weight loss drugs, available in 47 states and Washington, D.C., aimed at self-pay customers to enhance the company's competitive edge in health management.
- No Membership Fee: The service does not require a membership fee, further lowering the barrier for customer access, which is expected to attract more consumers seeking convenient healthcare services, thereby driving CVS's customer base and revenue growth.
- Medicare Participation Program: CVS announced its participation in the CMS Medicare GLP-1 Bridge program from July 1, 2026, to December 31, 2027, allowing eligible Medicare beneficiaries to purchase certain GLP-1 medications for $50 per month, enhancing the company's influence in the senior healthcare market.
- Positive Market Response: This new initiative is viewed as a compelling turnaround opportunity for CVS, with analysts expressing optimism about its improving financial metrics and potential market recovery, which is expected to elevate CVS's overall valuation in the healthcare sector.
See More
